Pfizer's Elrexfio Met Primary Endpoint Of PFS
Pfizer's Elrexfio Met Primary Endpoint Of PFS
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Pfizer Says ELREXFIO Phase 3 Trial Met Primary PFS Endpoint
Pfizer said MagnetisMM-32 met its primary endpoint, with ELREXFIO monotherapy reducing the risk of progression or death versus three standard regimens in RRMM. PFS was 68% at 18 months; median PFS was not yet reached. Overall survival data remain immature, and regulatory filings are planned.